Fenofibrate improves heart failure outcomes in patients with

Porto, Portugal: Recent data from the ACCORD Lipid trial showed that fenofibrate reduces the composite of HF hospitalizations or cardiovascular mortality in type 2 diabetes (T2D) patients treated with...

Related Keywords

Portugal , Porto , Pedro Ferreira , Diana Ferr , Abhinav Sharma , Francisca Saraiva , Patrick Rossignol , Adelino Leite Moreira , Francisco Vasques , Faiez Zannad , University Of Porto , Diabetes Care , Control Cardiovascular Risk , Francisco Vasques N , Heart Failure Outcomes , Patients With Type , Analysis From , Fenofibrate , Type 2 Diabetes , Heart Failure , Ef Hospitalization , Cardiovascular Mortality , Simvastatin , Lucose Lowering Therapy , Oão Pedro Ferreira , Diabetes , Hospitalization , Ccord Lipid Trial ,